Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?)
- PMID: 36858792
- DOI: 10.1016/j.jtha.2022.11.030
Evaluation and management of oral anticoagulant bleeding: quid didicimus? (what have we learned?)
Conflict of interest statement
Declaration of competing interests J.H.L. has served on Steering and Advisory Committees for Merck, Octapharma, and Werfen. J.M.C. has served on Scientific Advisory Boards of Abbott, Anthos, Alnylam, Bristol Myers Squibb, Five Prime Therapeutics, and Pfizer, and received research funding from CSL Behring.
Comment on
-
DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature.J Thromb Haemost. 2023 Mar;21(3):433-452. doi: 10.1016/j.jtha.2022.11.029. Epub 2022 Dec 22. J Thromb Haemost. 2023. PMID: 36696204 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
